Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01154127 · ClinicalTrials.gov registry record · Phase 3
Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 108
- Enrollment target
NCT01154127 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 108 participants.
The verdict
NCT01154127, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 108 participants
- Enrollment target
Study Summary
The ability for patients with COPD to exercise is limited due to the deterioration of their lung function. NVA237 is being developed to treat COPD. This study is designed to look at how well NVA237 improves the ability to exercise in patients with moderate to severe COPD.
Interventions
- DRUG Placebo
- DRUG NVA237
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01154127
The ClinicalTrials.gov registry entry for NCT01154127 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01154127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01154127 about?
NCT01154127 is a clinical study titled "Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)". The ability for patients with COPD to exercise is limited due to the deterioration of their lung function. NVA237 is being developed to treat COPD. This study is designed to look at how well NVA237 improves the ability to exercise in patients with moderate to severe COPD.
What is the current status of trial NCT01154127?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 108 participants. The study started on 2010-06. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01154127?
The interventions under investigation include: Placebo (DRUG), NVA237 (DRUG).
Who is sponsoring clinical trial NCT01154127?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.